Investigational Long-Acting Drug Safe in Phenotypic MASH

(MedPage Today) — Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed.
Among 65 participants treated with efimosfermin…